Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fentanyl buccal - Teva

Drug Profile

Fentanyl buccal - Teva

Alternative Names: E-fen buccal tablets; Effentora; Fentanyl buccal - Cephalon; Fentanyl citrate - Teva; Fentora; OraVescent® fentanyl; OVF

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CIMA LABS
  • Developer BMP Sunstone Corporation; CIMA LABS; M. D. Anderson Cancer Center; Taiho Pharmaceutical; Teva Pharmaceutical Industries
  • Class Amides; Benzene derivatives; General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain
  • Phase II Dyspnoea
  • Preregistration Submission Withdrawal Pain
  • Discontinued Neuropathic pain

Most Recent Events

  • 04 Dec 2019 Teva Pharmaceuticals completes a phase II trial in Dyspnoea (in cancer patients) in USA (Buccal) (NCT01856114)
  • 02 Aug 2019 Phase II development is still ongoing for Dyspnoea USA (NCT01856114)
  • 02 Aug 2019 No development reported - Phase-II for Dyspnoea in Germany (Buccal) (EudraCT2011-005797-32)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top